Navigation Links
Feinstein Institute researcher publishes new perspective on sepsis
Date:4/17/2014

MANHASSET, NY In a review published in the April issue of Immunity, Kevin J. Tracey, MD, president of The Feinstein Institute for Medical Research, says it's time to take a fresh look at the medical community's approach to treating sepsis, which kills millions worldwide every year, including more than 200,000 Americans.

Sepsis occurs when molecules released into the bloodstream to fight an injury or infection trigger inflammation throughout the body. Inflammation is necessary for maintaining good health without inflammation, wounds and infections would never be controlled or heal. However, persistent and constant inflammation often results in organ dysfunction or damage, leading to death 28 to 50 percent of people who suffer from sepsis die from the condition. In addition to the toll in human lives, sepsis costs healthcare systems billions of dollars each year much of the costs attributed to expenses incurred during weeks or months-long stays in intensive care units.

The review, co-written by Dr. Tracey and Clifford S. Deutschman, professor of Anesthesiology and Critical Care at the University of Pennsylvania, notes that unlike other major epidemic illnesses, treatment for sepsis is nonspecific and limited primarily to support of organ function and administration of intravenous fluids, antibiotics and oxygen. There are no approved drugs that specifically target sepsis. They argue that to develop therapeutic options that treat sepsis, a new approach might be needed.

Sepsis, Drs. Tracey and Deutschman wrote, "is not a stereotypical, steadily progressive immunological process that follows infection or injury; that innate and adaptive immune responses do not inevitably damage host cells; and that the long-held notion that sepsis is a distinct immunological disorder is incorrect. Rather, understanding sepsis requires reframing the research focus to identify immunometabolic and neurophysiological mechanisms of cellular and organ dysfunction."

The review explains that severe sepsis and persistent critical illness (PCI), which result in organ dysfunction that lasts for weeks or months, are not immunopathologies as previously thought. Immunopathology is a branch of medicine that deals with immune responses associated with disease. It includes the study of the pathology of an organism, organ system, or disease with respect to the immune system, immunity, and immune responses. Much of the efforts to treat sepsis have been focused in this area. Although much has been learned about sepsis and PCI as a result, this approach has not led to any currently approved targeted treatment.

Recent discoveries indicate that severe sepsis and PCI are not caused by immune system dysfunction alone, but also by a failure of homeostasis a failure in the body to maintain stability of its internal environment in response to changes in external conditions. Now that researchers know this, it will be crucially important to study aspects of homeostasis, including the deregulation of metabolism, neural reflexes, energy utilization and cell stress. Greater understanding in these areas has potential for resulting in improved and effective treatment for severe sepsis and PCI.


'/>"/>

Contact: Emily Ng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. Feinstein Institute Researcher Joins International Partnership in Neuroscience Research
2. Feinstein Institute researchers show a genetic overlap in schizophrenia and cognitive ability
3. Feinstein Researcher Receives 2013 Best of Manhasset Award
4. Feinstein Institute Encourages Science Education for NY Area Middle and High School Students
5. Feinstein Institute Researcher Organizes LI Alzheimer’s Consortium
6. Feinstein Institute to Receive $330,000 Grant to Support Research of Childhood Cancer
7. North Shore-LIJ Health System's Feinstein Institute to Receive $250,000 Grant from Lymphoma Research Foundation Grant to support research of Chronic Lymphocytic Leukemia
8. Summer Benefit Concert Raised More Than $1.5 Million for Feinstein Institute
9. Long Island Bike Challenge Rides to Raise Money for North Shore-LIJ's Feinstein Institute of Medical Research
10. Feinstein Institute, Hofstra North Shore-LIJ School of Medicine at 36th Annual Conference on Shock
11. North Shore-LIJ's Feinstein Institute Hosts Academic Commencement and Convocation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), ... into the US market. , Over the past 20 years SFI has been recognized ... SFI has launched six new clients into the US market. The new clients ...
(Date:1/19/2017)... ... 2017 , ... Each year, the Southeastern Society of Plastic ... of surgeons from over fifteen different countries come together to share and learn ... to breast reconstruction for breast cancer patients, teaching these surgical techniques which ...
(Date:1/18/2017)... ... ... A recent video posting of a new fidget product gathered online momentum as ... stress and anxiety. No one was more surprised than Think Ink Pen founders ... successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. “We’ve been in ...
(Date:1/18/2017)... ... 18, 2017 , ... Visually learn facts and tips on ... Certain Dri. , Excessive sweating and hyperhidrosis are common conditions that occur in ... explain the seven types of hyperhidrosis. This visual creates awareness about the condition ...
(Date:1/18/2017)... (PRWEB) , ... January 18, ... ... specialty pharmacy industry’s leading journal and most-read publication among specialty pharmacists and ... Medical Center through its Strategic Alliance Partnership (SAP) program, announced Brian Haug, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 18, 2017 The ... Food and Drug Administration (FDA) for its release ... and population health decision makers can proactively share ... products as well as emerging therapies awaiting FDA ... mirrors consensus recommendations that AMCP developed during two ...
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Breast Imaging Technologies ... projects that the global breast imaging technologies market size was ... reach $4,502 million by 2022, growing at a CAGR of ... and Europe together accounted for ...
Breaking Medicine Technology: